Industry

Data Highlighted in Poster Presentation at the National Lipid Association Scientific Sessions SCOTTSDALE, Ariz.–(BUSINESS WIRE)–#KnowFH–The Family Heart Foundation, a leading research and advocacy organization, completed an analysis of its large U.S. Family Heart DatabaseTM demonstrating that lipoprotein(a) – also referred to as Lp(a) — is rarely assessed, despite it being a common, independent risk factor … [Read more…]

Key research highlights include presentations on lung and ovarian cancers, value-based care, health technologies and health disparities THE WOODLANDS, Texas–(BUSINESS WIRE)–During the scientific program of the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting, principal investigators from US Oncology Research, The US Oncology Network (The Network) and Ontada® will present detailed results from more … [Read more…]

DUBLIN–(BUSINESS WIRE)–The “Graft Versus Host Disease (GvHD) Treatment Market Forecast – Epidemiology & Pipeline Analysis 2022-2027” report has been added to ResearchAndMarkets.com’s offering. The report considers the present scenario of the graft versus host disease market and its market dynamics for the period 2022-2027. It covers a detailed overview of several market growth enablers, restraints, … [Read more…]

WALTHAM, Mass.–(BUSINESS WIRE)–BostonGene today announced that three abstracts have been accepted for poster presentations and one abstract has been accepted for online publication for the 2022 ASCO Annual Meeting (ASCO), which will be held June 3 – 7, 2022, at McCormick Place Convention Center in Chicago, IL. BostonGene will also exhibit at booth 27087. “We … [Read more…]

New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology Clinical trials in locally advanced head and neck cancer and advanced bladder cancer seek to advance standards of care ROCKLAND, Mass.–(BUSINESS WIRE)–Not intended for UK-based media EMD Serono, the healthcare business of Merck KGaA, Darmstadt, Germany, in the US … [Read more…]

New data from DNA Damage Response (DDR) inhibitor portfolio inform development path for this promising biology Clinical trials in locally advanced head and neck cancer and advanced bladder cancer seek to advance standards of care Not intended for US-, Canada- or UK-based media DARMSTADT, Germany–(BUSINESS WIRE)–Merck, a leading science and technology company, today provided an … [Read more…]

Data from a phase 1/2 trial in patients with several subtypes of HER3 expressing metastatic breast cancer featured as oral presentation at ASCO First presentation of phase 1 data from a cohort of patients with advanced NSCLC without EGFR mutations also highlighted in poster discussion session TOKYO & MUNICH & BASKING RIDGE, N.J.–(BUSINESS WIRE)–New data … [Read more…]

MENLO PARK, Calif.–(BUSINESS WIRE)–ReCode Therapeutics, a biopharmaceutical company powering the next wave of genetic medicines through superior delivery, today announced that David Lockhart, Ph.D., President & Chief Scientific Officer of ReCode Therapeutics will present a corporate overview on Friday, June 10th from 11:00 – 11:25 a.m. ET at the Jefferies Healthcare Conference being held in … [Read more…]

Proceeds to accelerate standardization of single-cell spatial genomics research through broader adoption of Vizgen’s MERSCOPE™ Platform CAMBRIDGE, Mass.–(BUSINESS WIRE)–Vizgen, the life science company dedicated to improving human health by visualizing single-cell spatial genomics information, today announced the closing of $85.2 million Series C financing. The financing was led by Blue Water Life Science Advisors and … [Read more…]

New PDUFA goal date scheduled for September 29, 2022 to allow time to review additional data CAMBRIDGE, Mass.–(BUSINESS WIRE)–Amylyx Pharmaceuticals, Inc. (NASDAQ: AMLX) (“Amylyx” or the “Company”) today announced that the U.S. Food and Drug Administration (FDA) has extended the review timeline of the New Drug Application (NDA) for AMX0035 (sodium phenylbutyrate [PB] and taurursodiol … [Read more…]